Skip to main content

Published locations for Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies

User login

  • Reset your password
  • /content/meta-analysis-acalabrutinib-showed-better-pfs-and-os-other-frontline-cll-therapies
  • /fedprac/article/229606/cll/meta-analysis-acalabrutinib-showed-better-pfs-and-os-other-frontline-cll
  • /hematologynews/article/229606/cll/meta-analysis-acalabrutinib-showed-better-pfs-and-os-other
  • /oncologypractice/article/229606/cll/meta-analysis-acalabrutinib-showed-better-pfs-and-os-other
  • /hematology-oncology/article/229606/cll/meta-analysis-acalabrutinib-showed-better-pfs-and-os-other
  • /b-cell-lymphoma-icymi/article/229606/cll/meta-analysis-acalabrutinib-showed-better-pfs-and-os-other